Michael A. Caligiuri
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Area:
Immunology, Molecular Biology, Cell BiologyWebsite:
https://cancer.osu.edu/research-and-education/find-a-researcher/search-researcher-directory/michael-a-caligiuriGoogle:
"Michael Caligiuri"Children
Sign in to add trainee| Megan A. Cooper | grad student | 2002 | Ohio State |
| Laura J. Rush | grad student | 2003 | Ohio State |
| Sameek Roychowdhury | grad student | 2004 | Ohio State |
| Jeffrey B. VanDeusen | grad student | 2004 | Ohio State |
| Aharon G. Freud | grad student | 2006 | Ohio State |
| Adrienne M. Dorrance | grad student | 2008 | Ohio State |
| Susan E. McClory | grad student | 2012 | Ohio State |
| Edward L. Briercheck | grad student | 2013 | Ohio State |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li Z, Ma R, Tang H, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell |
| Mansour AG, Teng KY, Li Z, et al. (2023) Off-the-Shelf CAR-Engineered Natural Killer Cells Targeting FLT3 Enhance Killing of Acute Myeloid Leukemia. Blood Advances |
| Kumar A, Taghi Khani A, Duault C, et al. (2023) Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. Journal For Immunotherapy of Cancer. 11 |
| Yu J, Caligiuri MA. (2023) Viral- and tumor-reactive natural killer cells. Seminars in Immunology. 67: 101749 |
| Ma S, Han J, Li Z, et al. (2023) An XBP1s-PIM-2 positive feedback loop controls IL-15-mediated survival of natural killer cells. Science Immunology. 8: eabn7993 |
| Hong B, Sahu U, Mullarkey MP, et al. (2023) PKR induces TGF-β and limits oncolytic immune therapy. Journal For Immunotherapy of Cancer. 11 |
| Caligiuri M, Li Z, Ma R, et al. (2023) Human ILC1s target leukemia stem cells and control development of AML. Research Square |
| Tian L, Xu B, Chen Y, et al. (2022) Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nature Cancer |
| Ma S, Caligiuri MA, Yu J. (2022) Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends in Immunology |
| Lu T, Ma R, Dong W, et al. (2022) Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nature Communications. 13: 2576 |